Skip to main content

Table 1 Patient demographics and baseline characteristics (pooled analysis)

From: Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer’s disease

 

BI 409306

10 mg QD

(n = 77)

BI 409306

25 mg QD

(n = 74)

BI 409306

50 mg QD

(n = 76)

BI 409306

25 mg BID

(n = 76)

Placebo

(n = 149)

Male, n (%)

41 (53.2)

32 (43.2)

42 (55.3)

33 (43.4)

73 (49.0)

Age (years), mean (SD)

73.3 (7.7)

74.2 (7.8)

73.1 (6.1)

74.0 (8.4)

73.5 (7.4)

Race, n (%)

 Asian

1 (1.3)

0 (0)

1 (1.3)

0 (0)

0 (0)

 Black or African American

0 (0)

0 (0)

0 (0)

0 (0)

3 (2.0)

 White

76 (98.7)

74 (100.0)

75 (98.7)

76 (100.0)

146 (98.0)

Body mass index, (kg/m2), mean (SD)

26.0 (3.4)

27.2 (5.2)

26.7 (3.7)

25.5 (3.9)

26.2 (4.1)

Smoking status, n (%)

 Never smoked

38 (49.4)

47 (63.5)

43 (56.6)

44 (57.9)

79 (53.0)

 Ex-smoker

30 (39.0)

24 (32.4)

30 (39.5)

25 (32.9)

61 (40.9)

 Current smoker

9 (11.7)

3 (4.1)

3 (3.9)

7 (9.2)

9 (6.0)

Alcohol status, n (%)

 Non-drinker

36 (46.8)

30 (40.5)

29 (38.2)

37 (48.7)

72 (48.3)

 Drinks—no interference

41 (53.2)

44 (59.5)

47 (61.8)

39 (51.3)

77 (51.7)

 Drinks—possible interference

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

ApoE e4-positive, n (%)

 e3/e4

29 (37.7)

25 (33.8)

32 (42.1)

22 (28.9)

62 (41.6)

 e4/e4

5 (6.5)

8 (10.8)

7 (9.2)

11 (14.5)

15 (10.1)

NTB total

n

71

67

73

67

134

 Mean (SD)

0.05 (0.66)

− 0.12 (0.61)

0.01 (0.67)

0.05 (0.65)

− 0.03 (0.66)

 Median (range)

0.01 (−1.7–1.8)

− 0.09 (− 1.6–1.6)

− 0.03 (− 1.2–1.7)

0.12 (− 1.5–1.9)

0.05 (− 1.7–2.1)

ADAS-Cog11 total

n

70

66

69

69

129

 Mean (SD)

16.90 (7.79)

19.23 (7.70)

17.45 (8.05)

19.43 (8.7)

18.52 (8.31)

 Median (range)

16.33 (2.3–41.0)

19.00 (4.0–38.0)

15.67 (3.0–39.7)

17.33 (6.0–49.7)

17.00 (2.7–41.7)

CDR-SB total

n

75

73

76

74

148

 Mean (SD)

4.75 (2.13)

4.76 (2.23)

4.70 (2.17)

5.18 (2.78)

4.91 (2.43)

 Median (range)

4.50 (0.5–12.0)

4.50 (1.0–10.0)

4.50 (0.5–10.0)

5.00 (0.5–14.0)

4.50 (0.5–14.0)

  1. ADAS-Cog11 Alzheimer’s Disease Assessment Scale-cognitive subscale, ApoE e4 apolipoprotein E e4 allele, BID twice daily, CDR-SB Clinical Dementia Rating scale-Sum of Boxes, NTB Neuropsychological Test Battery, QD once daily, SD standard deviation